EUSA Pharma to acquire Janssen Ireland’s Sylvant for $115m
EUSA Pharma has signed a definitive agreement to purchase global rights for Sylvant (siltuximab) drug from Janssen Sciences Ireland for a cash consideration of $115m.
EUSA Pharma has signed a definitive agreement to purchase global rights for Sylvant (siltuximab) drug from Janssen Sciences Ireland for a cash consideration of $115m.
© Copyright Verdict Media Limited 2021
